PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. Europace. 2018;20:1929 35. CLINICAL STATEMENTS AND GUIDELINES Appendix 1. Author Relationships With Industry and Other Entities (Relevant) 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation (July 2018) Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals by Section* Craig T. January Chair University of Wisconsin- Madison Professor of Medicine, Cardiovascular Medicine Division None None None None None None None L. Samuel Wann Vice Chair Columbia St. Mary s Cardiovascular Physicians Clinical Cardiologist Astellas None None None None None None Hugh Calkins Johns Hopkins Hospital Professor of Medicine, Director of Electrophysiology Abbott AltaThera AtriCure Boehringer Ingelheim King Pharmaceuticals, Inc. (Pfizer) Medtronic St. Jude Medical None None Boehringer Ingelheim Boston Scientific St. Jude Medical Lin Y. Chen University of Minnesota Medical School, Cardiovascular Division Associate Professor of Medicine None None None None None None None Joaquin E. Cigarroa Oregon Health & Science University Professor of Medicine; Clinical Chief of Knight Cardiovascular Institute Division Head of Cardiology None None None None None None None Joseph C. Cleveland, Jr University of Colorado Professor of Surgery; Denver Veteran s Administration Hospital Chief, Cardiac Surgery None None None St. Jude Medical None None 4.4.1, 4.4.2, 6.3.4, Patrick T. Ellinor Massachusetts General Hospital Heart Center, Cardiac Arrhythmia Service Director Bayer None None Bayer None None 4.1.1, 4.2.2.2, 4.3, Michael D. Ezekowitz Sidney Kimmel Medical College at Thomas Jefferson University Professor of Medicine; Lankenau Medical Center, Bryn Mawr Hospital Attending Cardiologist Armetheon Bayer Boehringer Ingelheim Bristol-Myers Squibb Coherex Daiichi-Sankyo Janssen Pharmaceuticals Johnson & Johnson Medtronic Merck Pfizer Portola Pharmaceuticals Sanofi-aventis None None Boehringer Ingelheim (PI) Pfizer (PI) Portola Pharmaceuticals Michael E. Field Medical University of South Carolina and Ralph H. Johnson VA Medical Center Associate Professor of Medicine None None None None None None None Karen L. Furie Rhode Island Hospital, the Miriam Hospital and Bradley Hospital Neurologist-in-Chief; The Warren Alpert Medical School of Brown University Chair of Neurology None None None None None None None Paul A. Heidenreich Stanford VA Palo Alto Health Care System Professor of Medicine None None None None None None None Katherine T. Murray Vanderbilt University School of Medicine, Divisions of Clinical Pharmacology and Cardiology Professor of Medicine None None Metabolic Technologies, Inc. None None None None Julie B. Shea Brigham and Women s Hospital Medtronic St. Jude Medical None None None None None 4.4.1, 4.4.2, 7.4, (Continued) CLINICAL STATEMENTS AND GUIDELINES Cynthia M. Tracy George Washington University Medical Center Associate Director and Professor of Medicine None None None None None None None Clyde W. Yancy Northwestern University, Feinberg School of Medicine Magerstadt Professor of Medicine; Division of Cardiology Chief None None None None None None None This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. 